Genetic signatures related to telomere maintenance have emerged as powerful classifiers among CNS tumors. These include the alternative lengthening of telomeres (ALT) phenotype associated with mutations in the ATRX and DAXX genes and recurrent point mutations in the TERT gene promoter. We investigated a patient cohort covering the entire spectrum of childhood and adult ependymomas (n ¼ 128), including subependymomas and myxopapillary ependymomas, for the presence of TERT promoter mutations, for loss of ATRX or DAXX expression by immunohistochemistry (as surrogates as underlying gene mutations), and for the ALT phenotype by fluorescence in situ hybridization (FISH). TERT promoter mutations were identified in 9/120 (7%) of tumors, all of which were conventional ependymomas occurring in adults. TERT promoter mutations were associated with older age and intracranial localization. Remarkably, 2 of these tumors progressed to ependymosarcoma upon recurrence. No tumors displayed an ALT phenotype by FISH or were ATRX or DAXX deficient by immunohistochemistry. In sum, TERT promoter mutations are present in a subset of mostly intracranial conventional ependymomas in adults and may be relevant for the uncommon progression to ependymosarcoma. Loss of ATRX immunoreactivity is a useful marker to rule out ependymoma in specific diagnostic settings.
INTRODUCTION
Genetic signatures related to telomere maintenance have emerged as denominators of specific subgroups among gliomas. The two pertinent mechanisms are recurrent point mutations in the promoter region of the telomerase-reverse transcriptase (TERT) gene (1) and the alternative lengthening of telomeres (ALT) phenotype (2) . Oncogenic TERT promoter mutations counteract telomere shortening and thereby cell death in tumor cells by increasing telomerase expression (3), whereas ALT is a mechanism of telomere maintenance relying on homologous recombination and is independent of telomerase activity (4) . ALT may be detected by fluorescence in situ hybridization (FISH) for telomeric regions. It is associated with inactivating mutations in the a-thalassemia/mental retardation syndrome, x-linked (ATRX) or death-domain associated protein (DAXX) genes. These lead to loss of protein expression, which in turn can be demonstrated by immunohistochemistry (5) .
Loss of ATRX expression (as a surrogate of the ALT phenotype) and TERT promoter mutation status are important prognostic factors in diffusely infiltrative gliomas and are currently implemented as part of an integrative diagnostic approach to their classification (6) (7) (8) . Specifically, in conjunction with recurrent point mutations in the isocitrate dehydrogenase 1/2 (IDH1/IDH2) genes, ATRX deficiency is a quasi-defining feature of diffuse low-grade astrocytomas. Furthermore, it is frequent in high-grade astrocytomas with histone gene mutations (9) . Conversely, loss of DAXX expression has rarely been identified in gliomas, while it is common in pancreatic neuroendocrine tumors with the ALT phenotype (5) . TERT promoter mutations are present in the vast majority of IDH-wild-type glioblastomas and (in association with IDH mutations) in oligodendrogliomas (6) .
Limited data are available so far on TERT promoter mutations or the ALT phenotype in ependymomas, the third major morphological subgroup among gliomas besides astrocytomas and oligodendrogliomas. It has been suggested that both TERT promoter mutations and the ALT phenotype in a mutually exclusive fashion are characteristic of tumors derived from low-proliferative tissues (1) . In contrast to tumors originating from cell types with a high rate of self-renewal, these may need to gain a mechanism for telomere maintenance independent of intrinsic telomerase activity. According to this hypothesis, ependymomas could be expected to utilize either of these mechanisms.
In the present study, we sought to assess whether or not TERT promoter mutations and/or the ALT phenotype are present throughout the entire spectrum of ependymomas.
MATERIALS AND METHODS

Case Identification and Selection
We identified cases of ependymomas by full text search of our department's laboratory information system for the string "ependym*" for the period from 1990 to July 2013. We included all 4 major histological types of ependymal tumors as defined by the 4 th edition of the WHO classification (10) (For the sake of brevity, we use the term "ependymoma" interchangeably with "ependymal tumor" in this manuscript). Archival slides were retrieved and reviewed. For selected cases, additional immunohistochemical staining was performed in order to re-evaluate the diagnosis or to aid grading. Specifically, diffusely infiltrative gliomas, neurocytic tumors, astroblastoma and tumors with epithelial differentiation (including papillary tumor of the pineal region) were ruled out morphologically and if necessary by appropriate immunostaining. All cases were classified and graded according to the 4th edition of the WHO Classification of Tumours of the Central Nervous System (10).
Multiple specimens from any single patient were included only if the time course suggested that subsequent specimens represented progression or recurrence of the primary tumor and not residual tumor. We identified 143 potential specimens (136 surgical and 7 autopsy, respectively). Of these, 6 were excluded because the diagnosis of an ependymal neoplasm could not be confirmed. Additionally, 9 cases were excluded from further analysis due to an insufficient amount of available tumor tissue. This resulted in a total of 128 samples (from 108 patients).
The study was performed with approval of the ethics committee of the Canton of Bern (KEK 200/14).
Construction of Tissue Microarray
Tissue microarrays (TMAs) were constructed using our department's "next generation" TMA methodology, as previously described in (11) . Depending on the amount of available tumor tissue, one or 2 600-mm punches per specimen and recipient block were included and the TMA block was created in duplicate. An additional core was taken for DNA extraction.
ALT-FISH
FISH for telomeric regions was performed as previously described in (5) . Tumor tissues with known ALT status were used as positive and negative controls, respectively. ALT-FISH was evaluated by digital microscopy using an Olympus VS 110 fluorescence microscope/slide scanner. Spots with equivocal results were re-assessed directly under the fluorescence microscope.
Immunohistochemistry
Immunostaining for ATRX and DAXX was performed according to previously described protocols (5) with the following antibodies: anti-ATRX at a dilution of 1:400, and anti-DAXX 1:40 (both rabbit polyclonal antibodies; Sigma, St. Gallen, Switzerland). Staining of non-neoplastic cells (e.g. endothelial cells) was required as internal positive control in order for a core to be considered informative. For selected cases with equivocal results in the TMA analysis, ATRX and DAXX immunostaining was also performed on full histological sections.
In addition, the immunostainings for the following antigens were performed on the TMA: Olig2 (rabbit polyclonal); Sox10 (rabbit polyclonal); CD99 (clone 12E7), and nuclear factor jB (NFjB) (rabbit polyclonal).
TERT Promoter Mutation Analysis
The DNeasy Blood and tissue kit (Qiagen, Hombrechtikon, Switzerland) was used to extract DNA from all samples according to the manufacturer's instructions. In order to test for the 2 known mutations in the TERT promoter (C228T and C250T), DNA was amplified using forward primers 5 0 -CACCCGTCCTGCCCCTTCACCTT-3 0 and reverse primers 5 0 -GGCTTCCCACGTGCGCAGCAGGA-3 0 , generating an amplicon in which both mutation sites were included, followed by Sanger sequencing, as previously described (12) .
RESULTS
Patient Cohort
The characteristics of the definite patient cohort are summarized in Table 1 . The TMA included 121 surgical and 7 autopsy specimens; all but one of the latter were subependymomas.
Tissue samples of more than 1 tumor manifestation was available in 16 patients. Of these, there was 1 recurrence in 12 patients, 2 recurrences in 3 patients, and 3 recurrences in 1 patient. In patients with the tumor recurrences, the initial diagnosis was E-II in 9 patients, AE-III in 6 patients, and ME-I in 1 patient. In 1 patient there was progression from E-II to AE-III over the disease course. In 2 patients, recurrent tumors included a sarcomatous component, a phenomenon that has been referred to as "ependymosarcoma" (ES). One of these was previously published as a case report (13) .
ALT-FISH
ALT-FISH could be evaluated in 123 samples; of these, 2 cores were available for 108 cases. ALT was not identified in any of these. In the remaining 5 samples, ALT could not be assessed due to loss of the respective cores at the level of the stained slides or due to an insufficient number of neoplastic cells. In all cases that could be evaluated there was physiological regular fine, homogeneous staining pattern of telomeres (Fig. 1A) .
Immunohistochemistry for ATRX and DAXX
ATRX and DAXX immunohistochemistry could be evaluated in 109 and 115 samples, respectively. Of these in 90 and 100 cases, respectively, 2 cores could be assessed. For both ATRX and DAXX, normal nuclear staining was present in all cases that could be conclusively evaluated (Fig. 1B, C) . The remaining TMA spots lacked nuclear staining in both neoplastic as well as non-neoplastic (e.g. endothelial) cells and were considered as inconclusive because of a lack of an internal positive control. In the majority of these cases, both ATRX and DAXX staining were inconclusive. When immunostaining was repeated on full histological sections for selected cases, they showed areas with ATRX and DAXX staining present in tumor cells and non-neoplastic cells, indicating that the negative results in other regions were due to insufficient tissue antigenicity. There were no cases with ATRX or DAXX deficiency. In a total of 123 samples either ALT-FISH or both ATRX and DAXX could be assessed.
TERT Promoter Mutation Analysis
TERT promoter mutation analysis could be evaluated in a total of 120 specimens. In 9 of these (7%) cases, a mutation was identified (8 C228T mutations and 1 C250T mutation). All TERT promoter mutations occurred in conventional ependymomas diagnosed in adults (Table 2 ) and all but 1 was intracranial. Histological slides of all 9 TERT promoter mutant tumors were re-reviewed and the diagnosis of ependymoma was confirmed, even though they tended to show rather vague features of ependymal differentiation ( Fig. 2A, B) .
Importantly, they displayed a typical immunophenotype with regard to markers CD99, Olig2 and Sox10 (Supplemen  tary Table S1 ), which have been used to differentiate between ependymomas and diffuse gliomas (14, 15) . None of the TERT mutant tumors displayed nuclear NFjB staining; therefore, there was no evidence of an underlying RELA gene fusion, which is consistent with the adult age of onset.
Remarkably, TERT promoter mutations were present in the only 2 cases that exhibited a sarcomatous component upon recurrence (Table 2 ; Fig. 2C-I ). We subsequently assessed whether TERT promoter mutations were homogenously present in tumor tissue. In patient 8, the mutation was not identified in the primary, but an identical C228T mutation was present in 2 different areas of the recurrent tumor (Table 2) . In patient 9, C250T mutation was found in both the primary tumor and 1 region of the ES but not in a second region of the recurrent tumor. These findings suggest intratumoral heteroge- neity with respect to TERT promoter mutation status. TERT promoter mutations were associated with older age and intracranial location (Table 3) .
DISCUSSION
Until recently, there has been only very limited knowledge of the molecular pathogenesis of ependymomas. The syndromal occurrence of spinal cord ependymomas in the context of neurofibromatosis type 2 (NF2) led to the discovery that NF2 gene alterations are also present in a subset of sporadic spinal ependymomas (16) . Gain of chromosome 1q is an important negative prognosticator in pediatric ependymomas (17) . Otherwise, genetic markers have contributed little to the definition of biologically and/or clinically meaningful subgroups within the broad spectrum of ependymal tumors. Specifically, a number of genetic alterations relevant for the pathogenesis of other types of CNS tumors are not prevalent among ependymomas. These include TP53, IDH1/IDH2 mutations, 1p19q co-deletion, and MYC amplification (18) (19) (20) . A recent large comprehensive genetic analyses, however, has allowed the definition of a set of biological subgroups of ependymomas that account for much of their morphological, clinical and prognostic diversity (21) . Of these subgroups, RELA-fusion positive ependymoma is recognized as a distinct entity by the 2016 WHO Classification of Tumours of the Central Nervous System (22) . They account for a subset of (mostly childhood-onset) supratentorial ependymomas and are associated with an aggressive clinical course. The defining gene fusion results in activation of NFjB signaling (23) .
In this study, we investigated a cohort covering the entire spectrum of ependymal tumors with respect to histological type, patient age, and site and did not find evidence for a role of ALT in the pathogenesis of these tumors. As a corollary of this finding, loss of ATRX immunoreactivity can be considered robust evidence against ependymoma in the differential diagnosis with specific subsets of astrocytomas.
We identified TERT promoter mutations in nine adult conventional ependymomas. All but one were located intracranially, and these accounted for 18% of adult intracranial ependymomas. Review of histological slides confirmed the diagnosis even though features of ependymal differentiation were rather vague in some cases. Specifically, most of these were low-grade tumors diagnosed in resection specimens, which argues against the possibility of underdiagnosed or insufficiently sampled glioblastomas. Furthermore, the typical CD99þ/Olig2-/Sox10-immunoprofile distinguished these tumors from diffusely infiltrative gliomas (14, 15) . The absence of nuclear NFjB staining argues against the presence of a RELA gene fusion, as does the adult age of onset (23) . The statistical distribution of specific mutations (8 C228T mutations and 1 C250T mutation) was similar to previous reports of other tumor types (1).
Our findings are consistent with those of previous studies in specific ependymoma subgroups. Koelsche et al investigated a large series of neuroepithelial tumors that included 147 ependymal tumors, 7 (5%) of which showed TERT promoter mutations (24) . All mutated tumors occurred in adults and were E-II or AE-III; tumor sites were not reported. Killela et al found a single TERT mutation in 28 intracranial ependymomas (4%), while all 8 spinal ependymomas they investigated were TERT wild-type (1). They did not report on other pathological or clinical characteristics of these tumors. In a study published in abstract format only, Pekmezci et al. (25) found TERT promoter mutations in 7 out of 96 (7%) adult ependymomas, while all pediatric ependymomas were TERT wild-type. Furthermore, they found no ATRX-deficient ependymomas, but did not assess DAXX, or directly the ALT phenotype. In pediatric ependymomas, Barszczyk et al found no TERT promoter mutations, no ALT phenotype and no ATRX deficiency in 18, 56, and 41 tumors, respectively (26) . They concluded that increased telomerase activity independent of TERT promoter mutations is the only mechanism of telomerase maintenance in pediatric ependymomas and found increased telomerase activity to be an adverse prognostic factor, as are elevated TERT mRNA levels (27) .
Remarkably, TERT promoter mutations were identified in the only 2 tumors of our cohort that progressed to ES, an uncommon form of high-grade transformation of ependymomas (28) . Its genetic basis is unknown at present.
Our findings indicate that TERT-mutant ependymomas may be particularly prone to progress to ES. However, a direct role for TERT-mutations in sarcomatous transformation appears unlikely because TERT-promoter mutations were also present in conventional ependymomas. The intratumoral heterogeneity of TERT status further suggests that TERT mutations are likely not the principal genetic driver but a later event in tumorigenesis. This is similar to what was found in aggressive meningiomas (29) . Currently, only very limited information is available concerning the genetic features of ependymomas progressing to ES. A C11orf95-RELA fusion was reported in an ependymoma and its recurrence as sarcoma (30) . Two studies report various cytogenetic alterations in ES, all of which were shared by both components (28, 31) .
Further studies will be required to confirm the association of ES with TERT promoter mutations and to elucidate the underlying biological mechanisms of this rare form of tumor progression. 
